Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection

Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental neurology 2004-04, Vol.186 (2), p.248-251
Hauptverfasser:	Fagan, Susan C., Edwards, David J., Borlongan, Cesar V., Xu, Lin, Arora, Ankur, Feuerstein, Giora, Hess, David C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological and medical sciences Blood–brain barrier Brain - drug effects Brain - metabolism Cerebral circulation. Blood-brain barrier. Choroid plexus. Cerebrospinal fluid. Circumventricular organ. Meninges Chromatography, High Pressure Liquid - methods Dose Drug Administration Routes Drug Administration Schedule Fundamental and applied biological sciences. Psychology Human viral diseases Hydrogen-Ion Concentration Infectious diseases Intraperitoneal Male Medical sciences Minocycline Minocycline - administration & dosage Minocycline - blood Minocycline - cerebrospinal fluid Minocycline - pharmacokinetics Neuroprotection Neuroprotective Agents - administration & dosage Neuroprotective Agents - blood Neuroprotective Agents - cerebrospinal fluid Neuroprotective Agents - pharmacokinetics Pharmacokinetics Rats Rats, Sprague-Dawley Temperature Time Factors Vertebrates: nervous system and sense organs Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.
ISSN:	0014-4886 1090-2430
DOI:	10.1016/j.expneurol.2003.12.006